# SYK — Stryker Corporation

## Company & Research Metadata

- **Company:** Stryker Corporation
- **Ticker:** SYK
- **Exchange:** NYSE
- **Sector / Industry:** Health Care / orthopedics and medical technology
- **Template version:** 2.7
- **Research date:** 2026-10-21
- **Valuation / score price snapshot:** $310.55 — 2026-11-03 regular-session close, America/New_York
- **Tracking tier:** Primary Watchlist
- **Owned:** Yes
- **Primary operating period reviewed:** Q2 2026
- **Historical period reviewed:** TTM, FY 2025, FY 2024; latest balance-sheet date shown below
- **Latest investor presentation reviewed:** Results release and associated financial tables; no separate slide deck materially used
- **Latest earnings call reviewed:** Q2 2026, complete material Q&A
- **Latest post-earnings management commentary reviewed:** No separate later management presentation incorporated

- **Price snapshot date:** 2026-11-03

- **Price snapshot time / timezone:** Regular-session close, America/New_York (including exchange half-days)
- **Competitor / analyst-Q&A audit:** 2026-10-28; original operating, price and valuation snapshots retained.

## What's Changed Since Previous Review

**Current Review:** 2026-10-28

**Previous Review:** 2026-10-21

**Update Trigger:** Competitor relevance and analyst-Q&A correction

| Area | Previous View | Current View | Investment Impact |
|---|---|---|---|
| Competition | Preceding operating and comparable-company classifications | Product/customer/geographic boundaries corrected; direct rivals separated from substitutes, partners and valuation anchors | Corrects the competitive comparison; does not by itself re-underwrite the valuation |
| Analyst questions | Prior source-linked Q&A summaries | Complete questions and sentence-form management answers; all 13 existing rows retained | Improves readability while preserving the recorded exchange meaning |
| Valuation and scores | Approved operating/price snapshots, scenarios, scores and decisions | Preserved | No price refresh, rerank or change to valuation assumptions in this correction pass |

**Thesis:** No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

## Investment Snapshot

| Metric | Current View |
|---|---|
| Price Snapshot | $310.55 — 2026-11-03 regular-session close, America/New_York |
| Rating / Zone Status | Hold / Watch |
| Bear / Base / Bull Fair Value | $146.02 / $288.60 / $453.12 |
| Scenario Probabilities | 25% / 50% / 25% |
| Probability-Weighted Fair Value | $294.09 |
| Probability-Weighted Expected Return | -5.3% |
| Bear-Case Return | -53.0% |
| Strong Buy Zone | ≤ $160.62 |
| Buy Zone | >$160.62–$235.27 |
| Avoid Chasing Above | > $326.77 |
| Quality Score / Tier | 85.0 / Tier A |
| Opportunity Score / Rank | 50.1 / #44 of 76 |
| Risk Level | Medium |
| Tracking / Ownership | Primary Watchlist / Owned |

**Decision rationale:** SYK is **Hold / Watch** at $304.40, with -3.4% probability-weighted upside and -52.0% bear-case return. A strong procedure franchise and disciplined innovation can compound per-share earnings over time. Confidence is 72/100 because the earnings conversion, competitive and capital assumptions below remain conditional.

## Investment Thesis

A strong procedure franchise and disciplined innovation can compound per-share earnings over time. Q2 sales grew 9.4% to $6.589 billion, supporting the durability of demand. The valuation question is whether the entry price provides enough return after accounting for a premium-quality business that is already widely recognized. Product quality and capital allocation remain more important than short-term multiple expansion.

### What the Market May Be Mispricing

| Debate | Research judgment |
|---|---|
| Procedure growth and Mako utilization | A strong procedure franchise and disciplined innovation can compound per-share earnings over time. |
| Innovation, clinical quality and pricing | Surgeon adoption, procedure volumes, installed-system utilization and recurring implant contribution determine customer economics. |
| Acquisition returns, leverage and cash conversion | TTM FCF was about $4.70 billion and SBC $251 million, giving a stronger owner-cash profile than many growth peers. |

## Business Overview

Stryker sells orthopedic implants, surgical equipment, neurotechnology and other medical devices. Mako robotic systems support procedure adoption and implant demand, while consumables and service relationships create recurring revenue. Hospitals and surgeons value clinical outcomes, workflow, training and reliability. Acquisitions broaden the product portfolio but add integration and financing requirements.

### Business Takeaway

Stryker sells orthopedic implants, surgical equipment, neurotechnology and other medical devices. Surgeon adoption, procedure volumes, installed-system utilization and recurring implant contribution determine customer economics.

## Industry, TAM & Market Share

Aging populations, surgical access and robotic adoption support demand. Reimbursement, hospital budgets and competing implant and device platforms constrain growth. Capital systems and recurring implants have different economics and should not be combined into one undifferentiated TAM.

### Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

#### Competitive Scale / Position

| Company / Platform | Primary Position | Relative Scale | Growth Direction | Investment Relevance |
|---|---|---|---|---|
| Zimmer Biomet (ZBH) | Direct: orthopedic implants and robotic-assisted surgery | Product scope; no matched operating-scale series | Competes for orthopedic procedures | Customer choice in the stated segment only |
| Johnson & Johnson — DePuy Synthes | Direct: orthopedic implants and VELYS enabling technology | Product scope; no matched operating-scale series | Competes for joint-replacement adoption | Customer choice in the stated segment only |
| Smith+Nephew | Direct: orthopedics, sports medicine and surgical workflows | Product scope; no matched operating-scale series | Competes in selected musculoskeletal procedures | Customer choice in the stated segment only |
| Medtronic (MDT) | Segment-specific: neurovascular and selected surgical technology | Product scope; no matched operating-scale series | Limited procedure-level overlap | Customer choice in the stated segment only |

### Industry Takeaway

Capital systems and recurring implants have different economics and should not be combined into one undifferentiated TAM. The base case requires evidence of profitable adoption within that market.

## Customer Economics

Surgeon adoption, procedure volumes, installed-system utilization and recurring implant contribution determine customer economics. Training and workflow integration create switching costs. Pricing pressure and manufacturing or quality issues can offset volume growth, making cash margins and product mix important.

### Customer-Economics Takeaway

The economic test is Acquisition returns, leverage and cash conversion. Pricing pressure and manufacturing or quality issues can offset volume growth, making cash margins and product mix important.

## Competitive Landscape & Moat

### Competitive Landscape

Orthopedic implants and surgical robotics require orthopedic peers. Boston Scientific is removed as a broad device anchor; Medtronic is relevant only in identified neurovascular/surgical segments.

| Competitor | Market Share | Positioning | Advantages vs. Company | Disadvantages vs. Company | Current Direction |
|---|---|---|---|---|---|
| Zimmer Biomet (ZBH) | No consistent comparable series | Direct: orthopedic implants and robotic-assisted surgery | Implant installed base and ROSA ecosystem | Different surgical-equipment and neurotechnology mix | Competes for orthopedic procedures |
| Johnson & Johnson — DePuy Synthes | No consistent comparable series | Direct: orthopedic implants and VELYS enabling technology | Surgeon relationships and orthopedic portfolio | Parent pharmaceuticals do not represent device economics | Competes for joint-replacement adoption |
| Smith+Nephew | No consistent comparable series | Direct: orthopedics, sports medicine and surgical workflows | Specialized procedure products | Different business mix and robotics footprint | Competes in selected musculoskeletal procedures |
| Medtronic (MDT) | No consistent comparable series | Segment-specific: neurovascular and selected surgical technology | Hospital and neurological-device distribution | Not a joint-replacement implant competitor | Limited procedure-level overlap |

### Moat Assessment

Clinical reputation, surgeon relationships, installed robotics and distribution create a strong moat. Competitors remain well funded and can improve products. Sustaining the moat requires continuing clinical and engineering investment.

**Moat direction:** Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

### Competitive Takeaway

Clinical reputation, surgeon relationships, installed robotics and distribution create a strong moat. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

## Financial Profile

### Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

| Period | Revenue | Growth | Gross Margin | Operating Margin | FCF | FCF Margin | SBC | Diluted Shares | Cash | Debt |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| FY2024 | 22,595 | 10.23% | 64.37% | 21.93% | 3,487 | 15.43% | 229 | 386 | 4,493 | 14,120 |
| FY2025 | 25,116 | 11.16% | 65.04% | 22.92% | 4,283 | 17.05% | 243 | 387 | 4,100 | 16,360 |
| Q1 FY2026 | $6,020 | N/D | 63.3% | 15.5% | $415 (derived: CFO - capex) | 6.9% | $87 | 386.5 | $2,878 | N/D |
| Q2 FY2026 | $6,589 | N/D | 68.3% | 25.2% | $1,059 (derived: current YTD - prior YTD) | 16.1% | $54 (derived: current YTD - prior YTD) | 386 | $3,391 | N/D |
| H1 FY2026 | $12,609 | N/D | 65.9% | 20.6% | $1,474 (derived: CFO - capex) | 11.7% | $141 | 386.2 | $3,391 | N/D |
| Q3 FY2026 | $6,520 | N/D | 65.2% | 15.9% | $1,224 (derived: current YTD - prior YTD) | 18.8% | $67 (derived: current YTD - prior YTD) | 384.7 | $3,271 | N/D |
| 9M FY2026 | $19,129 | N/D | 65.6% | 19.0% | $2,698 (derived: CFO - capex) | 14.1% | $208 | 385.8 | $3,271 | N/D |

### Financial Takeaways

TTM FCF was about $4.70 billion and SBC $251 million, giving a stronger owner-cash profile than many growth peers. Debt remains material after acquisitions. Scenario EPS includes ongoing costs, while an assumed dividend stream is valued separately. The model does not rely on a return to historically high valuation multiples. The latest call described peripheral-vascular disruption and orthopedic backorders. The narrowed revenue outlook requires second-half recovery, including rescheduled procedures. Strong cash generation does not remove this operational dependency.

**Financial direction:** Mixed — assess the reported trend alongside dilution and the balance sheet.

## Management & Capital Allocation

Management has a strong record of execution and portfolio development. Acquisition discipline, integration returns and deleveraging remain relevant. Monitor organic growth and per-share cash returns rather than rewarding acquired revenue without considering price paid. Supply disruptions weaken the immediate execution assessment. M&A remains management's first capital-allocation priority, so acquisition returns should be tested alongside recovery of organic growth.

### Management Takeaway

M&A remains management's first capital-allocation priority, so acquisition returns should be tested alongside recovery of organic growth.

## Valuation

### Current Valuation

| Metric | Value |
|---|---|
| Price Snapshot | $310.55 — 2026-11-03 regular-session close, America/New_York |
| Market Capitalization | $116.76B |
| Enterprise Value | $128.73B |
| Trailing P/E | 31.55 |
| Provider forward P/E | 19.12 |
| EV / Sales | 4.98 |

### Comparable Company Analysis

| Company | Relevance | Public / Private | Forward P/E | EV / Sales | Growth / Margin / Risk Context |
|---|---|---|---|---|---|
| SYK — Stryker Corporation | Subject company | Public | 19.12 | 4.98 | orthopedics and medical technology; 3Y revenue-growth estimate 8.22%; operating margin 23.82% |
| ZBH — Zimmer Biomet | Direct orthopedic/robotics comparator | Public | 10.97 | 2.99 | orthopedic implants and surgical technology; 3Y revenue-growth estimate 3.94%; operating margin 16.65% |
| MDT — Medtronic plc | Segment-specific neurovascular/surgical overlap; not an orthopedic peer | Public | 15.76 | 3.60 | diversified medical devices; 3Y revenue-growth estimate 5.20%; operating margin 20.10% |
| Johnson & Johnson — DePuy Synthes | Direct: orthopedic implants and VELYS enabling technology | Operating product / listed parent | N/D — no matched snapshot collected | N/D — no matched snapshot collected | Competes for joint-replacement adoption |
| Smith+Nephew | Direct: orthopedics, sports medicine and surgical workflows | Public | N/D — no matched snapshot collected | N/D — no matched snapshot collected | Competes in selected musculoskeletal procedures |

**Comparable takeaway:** Orthopedic implants and surgical robotics require orthopedic peers. Boston Scientific is removed as a broad device anchor; Medtronic is relevant only in identified neurovascular/surgical segments. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 24×, versus the provider's current forward P/E of 19.12×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of **$231.51**, versus the central base FV of **$288.60**. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

### Valuation Scenarios

| Scenario | Key Assumptions | Fair Value | Probability | Probability Rationale | Return From Price Snapshot |
|---|---|---|---|---|---|
| Bear | 3Y revenue CAGR 4%; sustainable 2029 EPS $10.50 after compensation; 18× P/E; 11% discount rate; Slower procedures and pricing pressure leave 2029 sustainable EPS at $10.50. | $146.02 | 25% | Execution, financing or competitive setbacks remain credible | -53.0% |
| Base | 3Y revenue CAGR 8%; sustainable 2029 EPS $16.00 after compensation; 24× P/E; 11% discount rate; Steady innovation and operating leverage produce $16 of 2029 sustainable EPS. | $288.60 | 50% | Most likely operating trajectory, requiring measurable progress | -7.1% |
| Bull | 3Y revenue CAGR 12%; sustainable 2029 EPS $21.00 after compensation; 29× P/E; 11% discount rate; Strong procedure and platform adoption produce $21 of 2029 sustainable EPS. | $453.12 | 25% | Successful product conversion and operating leverage; not assured | +45.9% |
| **Probability-Weighted** | Sum of each scenario value × its probability | $294.09 | **100%** | Judgmental scenario probabilities | -5.3% |

### Valuation Takeaway

- **Primary valuation method:** Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
- **Cross-check methods:** Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in [the valuation workpaper](../valuation/watchlist_models_2026-10-21.md).
- **Key valuation dependencies:** Procedure growth and Mako utilization; Innovation, clinical quality and pricing; Acquisition returns, leverage and cash conversion. All forward figures are independent research assumptions, not company guidance or consensus.
- **Valuation confidence / Risk Level:** 72/100 / Medium. Scenario values are sensitive to sustainable earnings and terminal multiples.
- **Margin-of-safety conclusion:** Hold / Watch at $304.40. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

## Analyst Questions

The table consolidates related questions and follow-ups from each material participant in the complete call.

| Analyst / Firm | Core Question | Management Response | Research Read-Through |
|---|---|---|---|
| Joanne Wuensch / Citi | Why was the guidance range narrowed? | Management said recovery is progressing and the range reflects remaining uncertainty. | Treat the stated timetable as conditional on demonstrated execution. |
| Robbie Marcus / JPMorgan | What changed in underlying demand? | Management said peripheral vascular disruption was unexpected. | Confirm that this opportunity converts into profitable recurring demand. |
| Larry Biegelsen / Wells Fargo | What supports the second-half growth bridge and higher guidance floor? | Management said the higher floor reflects greater confidence. | Confirm that this opportunity converts into profitable recurring demand. |
| Ryan Zimmerman / BTIG | How do margins and outpatient care settings support EPS? | Management said margin execution and outpatient opportunities support earnings. | Require durable cash conversion after compensation and ongoing investment. |
| Travis Steed / Bank of America | How quickly can orthopedic supply recover? | Management said backorders delay a full recovery. | Confirm that this opportunity converts into profitable recurring demand. |
| Vik Chopra / BMO Capital Markets | Can management quantify the volume assumptions behind recovery? | Management did not quantify all recovery drivers. | Confirm that this opportunity converts into profitable recurring demand. |
| Matthew O'Brien / Piper Sandler | How does guidance reflect known operating problems? | Management said identified operational problems are incorporated into guidance. | Treat the stated timetable as conditional on demonstrated execution. |
| Vijay Kumar / Evercore ISI | How are acquisitions prioritized relative to buybacks? | Management said acquisitions remain the leading priority. | Judge allocation on per-share returns after financing and dilution. |
| Patrick Wood / UBS | What supports the Smart Care sales outlook? | Management said strong orders support later-year sales. | Confirm that this opportunity converts into profitable recurring demand. |
| Ravi Misra / Truist | When could vascular products and trial evidence contribute? | Management said approval and evidence timing remain uncertain. | Value the opportunity only as permissions and evidence mature. |
| Matt Taylor / Jefferies | How will disruption-related procedure delays affect recovery? | Management said rescheduled procedures contribute later. | Treat the stated timetable as conditional on demonstrated execution. |
| Mathew Blackman / TD Cowen | What is needed to accelerate Inari growth? | Management said supply fixes are needed for faster growth. | Confirm that this opportunity converts into profitable recurring demand. |
| Caitlin Roberts / Canaccord Genuity | How do innovation and manufacturing affect the full-year outlook? | Management maintained the narrowed full-year outlook. | Confirm that this opportunity converts into profitable recurring demand. |

### Analyst-Q&A Takeaway

The recovery bridge depends on resolving supply constraints and converting delayed procedures. Strong orders help, but management did not quantify every recovery driver; acquisition discipline remains relevant.

## Thesis Monitoring

| Driver | Current State | Positive Trigger / Catalyst | Negative Trigger / Falsifier | What It Changes |
|---|---|---|---|---|
| Procedure growth and Mako utilization | A strong procedure franchise and disciplined innovation can compound per-share earnings over time. | Revenue trajectory sustains approximately 8% annual growth on a comparable basis | Growth remains below the 4% bear assumption over a full operating cycle | Revenue outlook and scenario probabilities |
| Innovation, clinical quality and pricing | Surgeon adoption, procedure volumes, installed-system utilization and recurring implant contribution determine customer economics. | After-cost earnings progress toward the base implied net margin of 19.0% | Competition, credit losses or service costs make that margin trajectory unattainable | Margins, moat score and valuation multiple |
| Acquisition returns, leverage and cash conversion | TTM FCF was about $4.70 billion and SBC $251 million, giving a stronger owner-cash profile than many growth peers. | Financing and compensation remain consistent with 385.9M economic shares in the 2029 base case | Required capital or cumulative dilution materially exceeds the model without matching earnings | Financial score, confidence and downside value |

## Quality & Opportunity Scorecards

### Quality Score

| Component | Score | Weight | Weighted Contribution | Evidence |
|---|---|---|---|---|
| Business durability and economics | 91 | 25% | 22.8 | Surgeon adoption, procedure volumes, installed-system utilization and recurring implant contribution determine customer economics. |
| Moat and competitive position | 88 | 25% | 22.0 | Clinical reputation, surgeon relationships, installed robotics and distribution create a strong moat. |
| Growth runway and durability | 79 | 20% | 15.8 | Aging populations, surgical access and robotic adoption support demand. |
| Financial quality and balance sheet | 83 | 15% | 12.5 | TTM FCF was about $4.70 billion and SBC $251 million, giving a stronger owner-cash profile than many growth peers. |
| Management, governance and capital allocation | 80 | 15% | 12.0 | Management has a strong record of execution and portfolio development. |
| **Quality Score** | **85.0** | **100%** | **85.0** | Weighted score, independent of ownership and current price |

- **Quality Tier:** A
- **Speculative override:** None

### Opportunity Score

| Component | Raw Input | Normalized Score | Weight | Weighted Contribution |
|---|---|---|---|---|
| Quality | 85 | 85.0 | 30% | 25.5 |
| Probability-weighted upside | -5.3% | 39.4 | 35% | 13.8 |
| Bear-case downside | -53.0% | 0.0 | 20% | 0.0 |
| Risk / valuation confidence | 72 | 72.0 | 15% | 10.8 |
| **Opportunity Score** |  | **50.1** | **100%** | **50.1** |

- **Opportunity Rank:** #44 of 76
- **Zone Status:** Hold / Watch

## Portfolio Context

- **Tracking tier:** Primary Watchlist
- **Owned:** Yes
- **Tracking source of truth:** `my_watchlist.md`
- **Portfolio source of truth:** `portfolio/holdings.md`
- **Scoring independence:** Ownership, account, shares, position size and cost basis do not change research, valuation, Quality, Opportunity, rank or zones.

## Investment Decision History

| Timestamp | Price | Rating | Zone Status | Buy Zone | Strong Buy Zone | Avoid Chasing Above | Base FV | P/W FV | P/W Return | Quality | Opportunity / Rank | Change / Rationale |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-21 (America/New_York) | $304.40 | Hold / Watch | Hold / Watch | >$160.62–$235.27 | ≤ $160.62 | > $326.77 | $288.60 | $294.09 | -3.4% | 85.0 | 51.4 / #33 | Initial missing-file analysis; common-universe ranking; independent scenario assumptions |

---

## Material Sources

| Source | Type | Date / Period | What It Supports |
|---|---|---|---|
| [www.sec.gov](https://www.sec.gov/Archives/edgar/data/310764/000031076426000048/sykex991earningsq22026.htm) | Company IR / earnings filing | Q2 2026 | Latest operating results, guidance, products and financial supplement |
| [SYK complete earnings-call transcript](https://stockanalysis.com/stocks/syk/transcripts/658569-q2-2026/) | Transcript | Q2 2026 | Prepared remarks and all material Q&A exchanges |
| [SYK regular-session historical price](https://stockanalysis.com/stocks/syk/history/) | Market data | 2026-10-20 close | Common price used in returns, scores and zones |
| [SYK valuation statistics](https://stockanalysis.com/stocks/syk/statistics/) | Market data | 2026-10-20 close; ratios retrieved 2026-10-21 | Market capitalization, shares, quoted multiples and current ratios |
| [SYK historical income statement](https://stockanalysis.com/stocks/syk/financials/income-statement/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical income statement; source-native currency and definitions |
| [SYK historical balance sheet](https://stockanalysis.com/stocks/syk/financials/balance-sheet/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical balance sheet; source-native currency and definitions |
| [SYK historical cash flows](https://stockanalysis.com/stocks/syk/financials/cash-flow-statement/) | Standardized financial statements | Latest reported period and two preceding fiscal years | Historical cash flows; source-native currency and definitions |
| [Zimmer Biomet statistics](https://stockanalysis.com/stocks/zbh/statistics/) | Comparable-company market data | 2026-10-20 regular close | Peer multiples and financial context; public quote basis |
| [Medtronic plc statistics](https://stockanalysis.com/stocks/mdt/statistics/) | Comparable-company market data | 2026-10-20 regular close | Peer multiples and financial context; public quote basis |
| [2025 10-K — product categories and competitive markets](https://www.sec.gov/Archives/edgar/data/310764/000031076426000010/syk-20251231.htm) | Regulatory filing / primary product evidence | FY2025; checked 2026-10-28 | Orthopedic versus neuro/surgical device boundaries |
| [SEC XBRL company facts — SYK](https://data.sec.gov/api/xbrl/companyfacts/CIK0000310764.json) | Regulatory filing (as tagged) | FY2026, through 2026-09-30 | Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics |